Completed PHASE1 INTERVENTIONAL 7-arm NCT03056209

Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

A Dose Block-randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation, Phase I Clinical Study

Sponsor: Yungjin Pharm. Co., Ltd.

Conditions MELAS Syndrome Mitochondrial Respiratory Chain Deficiencies

Interventions KL1333 100 mg KL1333 200 mg KL1333 25 mg KL1333 400 mg KL1333 50 mg KL1333 600 mg KL1333 800 mg Placebo

Updated 8 times since 2017 Last updated: Apr 25, 2018 Started: Jun 26, 2017 Primary completion: Apr 16, 2018 Completion: Apr 16, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on MELAS Syndrome and Mitochondrial Respiratory Chain Deficiencies, this trial is completed. The trial is conducted by Yungjin Pharm. Co., Ltd. and has accumulated 8 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

May 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jan 2018 — May 2018 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2017 — Jan 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yungjin Pharm. Co., Ltd.

Data source: Yungjin Pharm. Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea